WO2019060595A1 - Médicament inhalable en poudre sèche comprenant du glycopyrronium - Google Patents

Médicament inhalable en poudre sèche comprenant du glycopyrronium Download PDF

Info

Publication number
WO2019060595A1
WO2019060595A1 PCT/US2018/052024 US2018052024W WO2019060595A1 WO 2019060595 A1 WO2019060595 A1 WO 2019060595A1 US 2018052024 W US2018052024 W US 2018052024W WO 2019060595 A1 WO2019060595 A1 WO 2019060595A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
dry powder
glycopyrronium
long
blend
Prior art date
Application number
PCT/US2018/052024
Other languages
English (en)
Inventor
Mukul C. Dalvi
Libo Wu
Original Assignee
Teva Branded Pharmaceutical Products R&D, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Branded Pharmaceutical Products R&D, Inc. filed Critical Teva Branded Pharmaceutical Products R&D, Inc.
Publication of WO2019060595A1 publication Critical patent/WO2019060595A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the embodiments relate to an inhalable medicament and to a process for preparing inhalable medicaments.
  • the medicaments are for treating respiratory disorders.
  • a range of classes of medicaments have been developed to treat respiratory disorders (e.g. asthma and COPD) and each class has differing targets and effects.
  • Bronchodilators are employed to dilate the bronchi and bronchioles, decreasing resistance in the airways, thereby increasing the airflow to the lungs.
  • Bronchodilators may be short-acting or long-acting. Short-acting bronchodilators provide a rapid relief from acute bronchoconstriction, whereas long-acting bronchodilators help control and prevent longer-term symptoms.
  • bronchodilators target different receptors in the airways. Two commonly used classes are anticholinergics and p 2 -agonists.
  • Anticholinergics block the neurotransmitter acetylcholine by selectively blocking its receptor in nerve cells.
  • anticholinergics act predominantly on the M 3 muscarinic receptors located in the airways to produce smooth muscle relaxation, thus producing a bronchodilatory effect.
  • LAMAs long-acting muscarinic antagonists
  • examples of long-acting muscarinic antagonists include aclidinium, darifenacin, darotropium, fesoterodine, glycopyrronium, oxitropium, oxybutynin, solifenacin, tiotropium, tolterodine, trospium and umeclidinium.
  • p 2 -Adrenergic agonists act upon the p 2 -adrenoceptors which induces smooth muscle relaxation, resulting in dilation of the bronchial passages.
  • Examples of long-acting p 2 -agonists include carmoterol, formoterol, indacaterol, olodaterol, salmeterol, tulobuterol and vilanterol.
  • inhaled corticosteroids are steroid hormones used in the long-term control of respiratory disorders. They function by reducing the airway inflammation.
  • inhaled corticosteroids include budesonide, beclomethasone, ciclesonide, flunisolide, fluticasone, mometasone and triamcinolone.
  • Dry powder inhalable medicaments containing one or a combination of active ingredients in particular a long-acting muscarinic antagonist or a combination of a long-acting muscarinic antagonist and a long-acting p 2 -agonist and/or inhaled corticosteroid, are known.
  • Examples of medicaments containing one or combination of active ingredients are disclosed in the art and set out in WO 2005/105043, WO 2004/019985, WO 2007/071313, WO 2008/102128, WO 201 1/069197 and WO 2015004243.
  • a dry powder formulation typically contains a micronised active ingredient and a coarse carrier.
  • the active ingredient needs to be in micronised form (typically it should achieve a mass median aerodynamic diameter of 1-10 ⁇ , more typically 2-5 ⁇ ). This size of particle is able to penetrate the lung on inhalation. However, such particles have a high surface energy and require a coarse carrier in order to be able to meter the formulation.
  • the coarse carrier is typically lactose, usually in the form of a-lactose monohydrate.
  • the micronised active ingredient is adhered to the surface of the coarse carrier and, on inhalation, the active ingredient separates from the coarse carrier and is entrained into the lung.
  • the coarse carrier particles are of a size that, after inhalation, most of them remain in the inhaler or deposit in the mouth and upper airways. In order to reach the lower airways, active ingredient particles must therefore dissociate from the carrier particles and become redispersed in the air flow.
  • High-energy, micronised active ingredient particles are highly cohesive and form larger unstable agglomerates.
  • the formation of such agglomerates contributes to poor powder flow and homogeneity, accelerated chemical degradation and suboptimal adhesion/dispersion (to/from the carrier).
  • Micronised long-acting muscarinic antagonists are particularly cohesive and hygroscopic, and are difficult to formulate as dry powders.
  • Glycopyrronium is a particularly hygroscopic long-acting muscarinic antagonist.
  • formulators have typically added a so-called ternary excipient to dry powder inhalable formulations comprising long-acting muscarinic antagonists.
  • Ternary excipients are used to potentiate problems associated with high-energy active ingredient particles. Including ternary excipients within dry powder formulations protects them from the ingress of moisture, which preserves homogeneity of the mixture, and in turn provides a stabilising effect.
  • Metal stearates or amino acids are commonly used as ternary excipients within inhalable dry powder formulations, and for formulations containing a long-acting muscarinic antagonist magnesium stearate is most commonly used.
  • Magnesium stearate is commonly used as a ternary excipient in dry powder inhalable formulations containing glycopyrronium.
  • a drawback of ternary excipients is that they are inhaled by the patient. They can build up in the lungs leading to undesirable side effects. They also add to the regulatory burden when seeking approval for the product.
  • dry powder inhalable medicaments comprising long-acting muscarinic antagonists wherein the medicament is stable, homogenous and is resistant to degradation.
  • the embodiments provide a dry powder inhalable medicament comprising glycopyrronium and a coarse carrier, wherein the medicament has a blend uniformity of ⁇ 10% of glycopyrronium, and wherein magnesium stearate is not present within the medicament.
  • the embodiments provide a homogenous dry powder inhalable medicament comprising glycopyrronium.
  • the medicament has an advantageous stability profile and does not require a ternary excipient.
  • Fig. 1 shows entrainment of an inhalable dry powder formulation into an airstream and detachment of micronised active ingredient from a coarse carrier under conditions of strong and weak adhesion (see Particulate Interactions in Dry Powder Formulations for Inhalation, X.M Zeng et al. Taylor & Francis, London, 2000).
  • Fig. 2 shows the blend uniformity data of the glycopyrronium bromide (GPB) medicament blend, fluticasone propionate, salmeterol xinafoate and glycopyrronium bromide (FSG) medicament blend, and the fluticasone propionate and salmeterol xinafoate (FS) blend.
  • GPB glycopyrronium bromide
  • FSG glycopyrronium bromide
  • FSG glycopyrronium bromide
  • Fig. 3 shows the maintenance of the aerodynamic particle size distribution of glycopyrronium bromide in a mono product over 3 months under accelerated stability testing conditions, as measured using a next generation impactor.
  • Fig. 4 shows the maintenance of the aerodynamic particle size distribution of fluticasone propionate in a fluticasone/salmeterol/glycopyrronium combination product over 3 months under accelerated stability testing conditions, as measured using a next generation impactor.
  • Fig. 5 shows the maintenance of the aerodynamic particle size distribution of salmeterol xinafoate in a fluticasone/salmeterol/glycopyrronium combination product over 3 months under accelerated stability testing conditions, as measured using a next generation impactor.
  • Fig 6 shows the maintenance of the aerodynamic particle size distribution of glycopyrronium bromide in a fluticasone/salmeterol/glycopyrronium combination product mono product over 3 months under accelerated stability testing conditions, as measured using a next generation impactor.
  • the embodiments relate to a dry powder inhalable medicament which contains glycopyrronium and a coarse carrier, where the medicament has a blend uniformity of ⁇ 10% without recourse to magnesium stearate or other ternary agents.
  • the embodiments also provide combination products containing a long-acting muscarinic antagonist, such as glycopyrronium, together with a long-acting p 2 -agonist and/or an inhaled corticosteroid.
  • the dry powder inhalable medicaments containing glycopyrronium and a coarse carrier and combination products containing a long-acting muscarinic antagonist together with a long-acting p 2 -agonist and/or an inhaled corticosteroid and a coarse carrier each have advantageous blend uniformity of ⁇ 10% of glycopyrronium/LAMA (where appropriate).
  • the formulation of the embodiments advantageously has a high blend uniformity. It also advantageously provides a medicament with a stable (i.e. consistent over time) aerodynamic particle size distribution, and thus provides a medicament capable of maintaining a consistent delivered dose.
  • the delivered dose is dependent upon the aerodynamic particle size distribution (APSD) of the active ingredient particles, and refers to the amount of active ingredient which enters a patient's lung upon actuation of an inhaler device
  • the APSD is measured using a cascade impactor.
  • Cascade impactors comprise a series of plates each perforated with holes which reduce in size moving from plate to plate. Active ingredient particles enter the impactor in an air stream (typically 60 L/min) and are separated and collected by the plates according to particle size.
  • Pharmacopoeias recommend the use of several commercially available cascade impactors for determining APSD. Each impactor comprises different plates with different particle size "cut-off diameters.
  • the impactor used in conjunction with the present embodiments is a next generation impactor (NGI).
  • NTI next generation impactor
  • the NGI apparatus has defined cut-off diameters across seven plates or "stages" of the impactor, and the cut-off diameters are defined relative to a particular flow rate of air.
  • the cut-off diameters for the NGI are, stage 1 (8.06 ⁇ ), stage 2 (4.46 ⁇ ), stage 3 (2.82 ⁇ ), stage 4 (1.66 ⁇ ), stage 5 (0.94 ⁇ ), stage 6 (0.55 ⁇ ), stage 7 (0.34 ⁇ ) (refers to particle size MMAD in ⁇ ).
  • stage 1 (8.06 ⁇
  • stage 2 (4.46 ⁇ )
  • stage 3 (2.82 ⁇ )
  • stage 4 (1.66 ⁇
  • stage 5 (0.94 ⁇
  • stage 6 (0.55 ⁇
  • stage 7 (0.34 ⁇
  • the higher the amount of particles (by weight) of an inhalable size typically an MMAD of 1-5 ⁇ or collected at stages 2 to 4 of the NGI
  • the blend uniformity and stability of the present formulation is provided without reliance on magnesium stearate or other ternary agents.
  • High surface energy primarily results from particle size, and hence micronised active ingredients are considered high-energy particles.
  • a secondary contributor to surface energy originates from inherent electrostatic effects, which are a product of the chemical composition and structural architecture of an active ingredient. The electrostatic properties and behaviour of a particular compound result from Van der Waals forces (distance dependent interactions between atoms) which are known to be responsible for inter alia cohesion within powders.
  • the chemical composition and structural architecture of an active ingredient will determine its electrostatic makeup and thus its stability based upon the inter- and intra-particle interactions with neighbouring particles and the broader environment (e.g. atmospheric water vapour).
  • the chemical composition and structure of long-acting muscarinic antagonists is particularly problematic from an electrostatic viewpoint.
  • Long-acting muscarinic antagonists are quaternary ammonium salts and are therefore inherently cohesive and hygroscopic.
  • the moisture absorption associated with this class of compounds is particularly prominent when regions of amorphous character are present on the surface of the particles.
  • the size reduction step is necessary to break down particles into a smaller size (i.e. inhalable size) but by-products of this step are that the amount of electrostatic energy within the bulk powder is increased, and the surface amorphous character is also increased.
  • the embodiments potentiate the contribution of electrostatic energy to the total surface energy of the powder, and allows glycopyrronium to be formulated as a stable and homogenous dry powder inhalable medicament without the presence of magnesium stearate or any other ternary excipient.
  • the embodiments protect the long-acting muscarinic antagonist sufficiently such that ternary excipients are not required to stabilise the formulation.
  • the embodiments provide a dry powder inhalable medicament comprising glycopyrronium and a coarse carrier, wherein the medicament has a blend uniformity of ⁇ 10% of glycopyrronium, and wherein a ternary excipient is not present within the medicament.
  • Ternary excipients are well known in the art. They are also known as force control agents, lubricants and anti-adherents. They use the term "ternary" because they add a third material to the formulation over the active ingredient and the carrier. It should be noted that the coarse carrier inherently contains some fine particles of the same material (e.g. coarse lactose contains fine lactose). Such fine particles composed of the same material as the coarse carrier are not ternary agents.
  • ternary agents which are not required in the medicament of the present embodiments include metal stearates (such as magnesium and calcium stearate), fatty acids (e.g. stearic acid), amino acids (such as leucine) and phospholipids (such as lecithin).
  • the embodiments also provide a dry powder inhalable medicament consisting of glycopyrronium, optionally one or more additional active ingredients, a coarse carrier and optionally fine particles composed of the same material as the coarse carrier, wherein the medicament has a blend uniformity of ⁇ 10% of glycopyrronium.
  • Fine particles composed of the same material are fine particles that are inherently present and contained within the coarse carrier (as received from a commercial supplier). Such fine particles typically have a particle size of less than 10 ⁇ in size, more likely 1-5 ⁇ .
  • Inherent fine content contained within the coarse carrier can be measured by laser diffraction in air, e.g. with a Sympatec HELOS/BF equipped with a RODOS dispenser and VIBRI feeder unit. Fine particles of same material as the coarse carrier may also be deliberately added to the medicament. They are not considered to be a ternary agent because they do not introduce a third substance beyond the active and the carrier particles.
  • the embodiments also provide a process for preparing a dry powder inhalable medicament comprising glycopyrronium and a coarse carrier, wherein the glycopyrronium and the coarse carrier are mixed using a low-energy mixing process, and wherein magnesium stearate is not present within the medicament. Again, it is preferable that a ternary excipient is not present within the medicament.
  • the embodiments also provide a process for preparing a dry powder inhalable medicament consisting of glycopyrronium, optionally one or more additional active ingredients, a coarse carrier and optionally fine particles composed of the same material as the coarse carrier, wherein the medicament has a blend uniformity of ⁇ 10% of glycopyrronium.
  • the process involves mixing micronised glycopyrronium and a coarse carrier using a low-energy mixing process.
  • the glycopyrronium is micronised using a wet polishing process.
  • Wet polishing is a process used for reducing the particle size of active ingredients, and typically comprises wet milling, specifically by cavitation at elevated pressure.
  • an active ingredient is preferably suspended in a liquid (water or an organic solvent) in which it is insoluble, the suspension is then spray dried to obtain a dry powder having the desired particle size.
  • Wet polishing is preferred as it is known to avoid imparting amorphous character into the active ingredient which is under-going micronisation.
  • the process used to prepare the medicament of the embodiments utilises a low- energy mixing process.
  • the process minimises the total amount of kinetic energy being applied to the medicament blend, which reduces electrostatic build up and total surface energy.
  • a reduction in overall energy limits the formation of agglomerates and absorption of water, maximises stability and maintains beneficial inhalable dry powder properties.
  • Powder mixing is one of the most critical processes in providing a DPI formulation, insofar as the mixing conditions and apparatus can directly influence aerolisation performance. Unlike fluid mixing, wherein the mixing of two components is governed simply by a concentration gradient, powder particles require an input of energy (i.e. kinetic energy) to facilitate mixing. Therefore, a powder mixing apparatus is required to induce motion either by rotational/translational movement of a container in which the powder or medicament is contained, or alternatively the powder or medicament is moved by contact with an impeller or chopper that is contained within the powder mixing vessel.
  • energy i.e. kinetic energy
  • a mixing technique specific to dry powder inhaler technology is applied. This mixing technique is based upon the use of a tumbling mixer (sometimes referred to as “blenders”) (e.g. Turbula® and V-blenders) which are used for low-energy mixing.
  • a tumbling mixer sometimes referred to as “blenders”
  • Turbula® and V-blenders are used for low-energy mixing.
  • a tumbling mixer container is typically mounted within a frame upon a mixing apparatus.
  • the container is supported so that it can be rotated about an axis.
  • the tumbling action creates circular mixing zones and paths within the container.
  • tumbling mixers mix powder under the force of gravity as the mixer tumbles (i.e. rotates).
  • the interactions of the powder particles with each other and against the walls of the mixer cause shear mixing to occur.
  • the strength of the shear force experienced by a powder or substrate within a mixture is dependent upon the speed of mixing.
  • the principles of shear mixing are known within the common general knowledge, and for example are discussed in Aulton's Pharmaceutics: The Design and Manufacture of Medicines, M. E.
  • the speed of mixing contributes to the total amount of energy delivered to a powder during mixing.
  • the speed is measured in revolutions per minute (rpm) and refers to rotation of the container in which the powder is held.
  • rpm revolutions per minute
  • low-energy mixing can be achieved with a mixing apparatus having a vessel containing the powder which is rotated to impart a tumbling motion to the powder.
  • These mixers provide efficient powder mixing through the exertion of rotational and translation movement into the bulk powder and thus mix the powder under the force of gravity (i.e. indirect mixing).
  • the mixers are also suitable for the homogenous mixing of powders with differing specific weights and particle sizes. Typical mixers capable of providing this motion are known in the art.
  • the Turbula® is one such example.
  • the process used to prepare the medicament of the embodiments utilises a low- energy mixing step. It is most preferred wherein the low-energy mixing process is performed in a mixing apparatus operating at below 150 revolutions per minute (rpm). It is also preferred wherein the low-energy mixing process is performed in a mixing apparatus operating at 1-100 rpm. It is also preferred that the low-energy mixing process is conducted for a duration of at least 5 minutes, more preferably 10-60 mins.
  • the process used to prepare the medicament of the embodiments provides a homogenous dry powder inhalable medicament comprising glycopyrronium with an advantageous stability profile by maintaining low overall energy input into the powder.
  • the process also provides a dry powder inhalable medicament wherein the glycopyrronium within the mixture displays an advantageous aerodynamic particle size distribution, fine particle fraction and fine particle dose characteristics.
  • the process used to prepare the medicament of the embodiments is particularly advantageous because it obviates the need for including magnesium stearate or any other ternary excipient within the formulation.
  • the embodiments also provide a dry powder inhalable medicament obtainable by the process as set out herein.
  • the powder medicament is distinguished over powders prepared by other techniques based on the different interaction between the actives and the carrier, as evidenced by the blend uniformity, stability and the maintenance of the aerodynamic particle size distribution.
  • the glycopyrronium is also in a more stable form, with low levels of amorphous character, electrostatic charge and hygroscopicity.
  • the embodiments also provide a dry powder inhalable medicament comprising glycopyrronium and a coarse carrier, wherein the medicament has a blend uniformity of ⁇ 10% of glycopyrronium, and wherein magnesium stearate is not present within the medicament or wherein a ternary excipient is not present within the medicament and wherein the medicament comprises one or more additional active ingredients.
  • the one or more additional active ingredients comprise long-acting ⁇ 2 - agonists and/or inhaled corticosteroids.
  • the double and triple combination products comprise a combination of a long-acting muscarinic antagonist together with a long-acting p 2 -agonist and/or an inhaled corticosteroid.
  • the long-acting muscarinic antagonist is stabilised within the double and triple combinations respectively through using a low-energy mixing step to mix long-acting muscarinic antagonist with coarse carrier and a further low-energy mixing step to mix the long-acting muscarinic antagonist and coarse carrier blend with additional active ingredients. It is preferred that within double and triple combination dry powder inhalable medicaments provided by the embodiments, the glycopyrronium/LAMA (as appropriate) present within said double and triple combination products is micronised using a wet polishing process as described hereinabove.
  • the embodiments provide medicaments with excellent stability profiles. That is, the physical and chemical stability of glycopyrronium in single active ingredient and combination formulations is maintained on storage. Stability is assessed by wrapping formulations with foil containing a desiccant and placing samples in an accelerated testing chamber at 40°C and 75% RH (relative humidity). These testing conditions have been abbreviated to ACC where appropriate.
  • the physical stability is assessed by measuring and comparing the aerodynamic particle size distribution over time, for example over three months.
  • the measurement is conducted using a cascade impactor as mentioned hereinabove, preferably a next generation impactor.
  • the chemical stability is assessed by high-performance liquid chromatography (HPLC) following storage of the product under accelerated testing conditions.
  • HPLC high-performance liquid chromatography
  • the total impurity content remains well under the key value of 1.5% i.e. greater than 98.5% glycopyrronium/LAMA (as appropriate) remain. This suggests a shelf-life of at least 24 months at 25°C.
  • the embodiments also provide a physical stability of the glycopyrronium/LAMA (as appropriate) defined by a decrease in fine particle fraction (FPF) after three months of less than 10%, preferably less than 5%.
  • FPF fine particle fraction
  • the embodiments also provide for a dry powder inhalable medicament comprising glycopyrronium and a coarse carrier, wherein the glycopyrronium is chemically and physically stable after three months ACC wherein magnesium stearate is not present within the medicament, and preferably wherein a ternary excipient is not present within the medicament.
  • the embodiments also provide a process for preparing a dry powder inhalable medicament comprising a combination of a long-acting muscarinic antagonist and long-acting p 2 -agonist and/or inhaled corticosteroid, wherein the process comprises the steps of: (i) preparing a mixture of the long-acting p 2 -agonist and/or the inhaled corticosteroid and a first portion of the coarse carrier to form a first blend using a high-energy mixing process;
  • the process provides a double or triple combination dry powder medicament product with an advantageous stability profile and high homogeneity.
  • the process used to provide a double or triple combination dry powder medicament product comprising a long- acting muscarinic antagonist protects the long-acting muscarinic antagonist sufficiently such that ternary excipients are not required for stabilisation.
  • the double or triple combination dry powder medicament products comprising a long-acting muscarinic antagonist do not contain a ternary excipient.
  • the double or triple combination dry powder medicament products do not contain a metal stearate.
  • the double or triple combination dry powder medicament products do not contain magnesium stearate.
  • the embodiments provide a process to prepare a dry powder inhalable medicament comprising a combination of a long-acting muscarinic antagonist and long-acting p 2 -agonist and/or inhaled corticosteroid, wherein the process comprises the steps of:
  • the long-acting muscarinic antagonist has a blend uniformity of ⁇ 10% of the long-acting muscarinic antagonist, and wherein a ternary excipient is not present within the medicament or a metal stearate is not present within the medicament or wherein magnesium stearate is not present within the medicament.
  • the long-acting muscarinic antagonist used within the processes to prepare double and triple combination medicaments is micronised using a wet polishing process as described hereinabove.
  • High blend uniformity advantageously provides double and triple combination medicaments with stable (i.e. consistent over time) aerodynamic particle size distributions, and thus provides medicaments capable of maintaining a consistent delivered dose.
  • mixing techniques are based upon tumbling mixers (sometimes referred to as “blenders") (e.g. Turbula® and V-blenders) which are used for low-energy mixing, and high-speed mixers (e.g. PharmaConnect®) which use a mixing arm (e.g. an impeller or chopper or combination thereof) for high- energy mixing.
  • blenderers sometimes referred to as “blenders”
  • Turbula® and V-blenders e.g. Turbula® and V-blenders
  • high-speed mixers e.g. PharmaConnect®
  • a mixing arm e.g. an impeller or chopper or combination thereof
  • the low-energy mixing step is applied as discussed hereinabove in relation to mixing glycopyrronium and a coarse carrier.
  • a mixer typically comprises a container having a mixing arm within the container.
  • a mixing arm is an impeller blade or a chopper blade or a combination thereof.
  • Impeller blades are typically centrally mounted within the mixer at the bottom of the container.
  • Chopper blades are typically located on the side wall of the mixing container.
  • the mixing arm directly contacts the particles of active ingredient and coarse carrier, and imparts force into the powder.
  • the mixing arm rotates at a variable (high) speed, for example in the range of 50-500 revolutions per minute (rpm). In doing so, the mixing arm throws powder from the centre of the mixing bowl towards the wall by centrifugal force. The powder is then forced upwards before resting back towards the centre of the mixing arm.
  • the mixer has a plurality of mixing arms (typically an impeller and a chopper), the rpm values set out above and below correspond to the cumulative rpm values of both arms.
  • the main processing factor is the rotational speed of the mixing arm. The speed of the arm is measured in revolutions per minute (rpm).
  • high-energy mixing can be achieved with a mixing apparatus comprising a mixing arm, typically an impeller blade or a chopper blade or a combination thereof.
  • a mixing arm typically an impeller blade or a chopper blade or a combination thereof.
  • the impeller blade and/or chopper blade impart kinetic energy into the powder and also generate frictional, inertial and shear force (forces capable of de-agglomerating active ingredients).
  • An example of such a mixer is a PharmaConnect® high-shear mixer.
  • High-energy mixing occurs by contacting of the mixing arm with the powder (i.e. direct mixing) at high speed.
  • the high-energy mixing process is performed in a mixing apparatus operating at, in the range of 50-500 revolutions per minute (rpm) and wherein the low-energy mixing process is performed in a mixing apparatus operating in the range of 1-100 revolutions per minute (rpm).
  • the high-energy mixing process is performed in a mixing apparatus operating at 50-5000 rpm and wherein the low-energy mixing process is performed in a mixing apparatus operating at 1-100 rpm. It is also preferred wherein the high-energy mixing process is performed in a mixing apparatus operating at 350- 3500 rpm and wherein the low-energy mixing process is performed in a mixing apparatus operating at 1-100 rpm. It is also preferred wherein the high-energy mixing process is performed in a mixing apparatus operating at 350-2500 rpm and wherein the low-energy mixing process is performed in a mixing apparatus operating at 1-100 rpm.
  • the high-energy mixing process is conducted for a duration of at least 5 minutes, more preferably 10-90 mins. It is also preferred that the low-energy mixing process is conducted for a duration of at least 5 minutes, more preferably 10-60 mins.
  • the medicament is prepared by mixing the first and second blends using a low-energy mixing process for a duration of at least 5 minutes, more preferably 10-60 mins.
  • the total mixing time for providing the first and second blends and the medicament blend does not exceed two hours.
  • the independent mixing processes of the embodiments are conducted for at least five minutes to allow adequate homogeneity, deagglomeration of active ingredients or adhesion of active ingredient to coarse carrier to occur.
  • the process to provide a double or triple combination dry powder medicament provides a homogenous and stable double or triple combination powder blend and maintains low overall energy input into the powder.
  • the process also provides a dry powder inhalable medicament wherein each of the individual active ingredients within the mixture displays an advantageous aerodynamic particle size distribution, fine particle fraction and fine particle dose characteristics.
  • the administration of a single dose of two or three different classes of active ingredient also increases patient compliance.
  • the low energy processes conducted in conjunction with the process to provide double or triple combination dry powder medicaments are useful to manage chemically sensitive active ingredients e.g. long-acting muscarinic antagonists, whereas the high energy processes are useful to break down drug agglomerates as well as provide good distribution of active ingredient upon carrier.
  • the glycopyrronium-containing or long-acting muscarinic antagonist- and long-acting ⁇ 2 - agonist- and/or inhaled corticosteroid-containing medicaments display homogeneous blend uniformity.
  • homogeneous refers to a powder wherein, upon mixing, the uniformity of distribution of a component, expressed as coefficient of variation (CV) also known as relative standard deviation (RSD), is less than 5.0%. It is usually determined according to known methods, for instance by taking preferably greater than 10 samples from different parts of the powder and testing the component by HPLC or other equivalent analytical methods. A lower RSD of the blend results in a higher uniformity of the delivered dose, which is useful from a clinical and regulatory perspective.
  • CV coefficient of variation
  • RSD relative standard deviation
  • the blend uniformity of the medicaments described herein are homogenous.
  • the embodiments achieve a blend uniformity of ⁇ 10% of glycopyrronium/LAMA (as appropriate), more preferably ⁇ 5% of glycopyrronium/LAMA (as appropriate).
  • the blend uniformity is determined by HPLC or equivalent methods as discussed hereinabove.
  • the process of the embodiments provides a dry powder inhalable medicament comprising glycopyrronium, preferably glycopyrronium bromide.
  • the process of the embodiments also provide a dry powder inhalable medicament comprising a combination of long-acting muscarinic antagonist, long-acting p 2 -agonist and/or inhaled corticosteroid.
  • the long-acting muscarinic antagonist is preferably aclidinium (bromide), darifenacin (hydrobromide), darotropium (bromide), fesoterodine (fumarate), glycopyrronium (bromide), oxitropium (bromide), oxybutynin (hydrochloride or hydrobromide), solifenacin (succinate), tiotropium (bromide), tolterodine (tartrate), trospium (chloride) and umeclidinium (bromide). More preferred are glycopyrronium (bromide) and tiotropium (bromide), and most preferred is glycopyrronium (bromide).
  • the long-acting p 2 -agonist is preferably carmoterol (hydrochloride), formoterol (fumarate), indacaterol (maleate), olodaterol (hydrochloride), salmeterol (xinafoate), tulobuterol (hydrochloride) and vilanterol (trifenatate). More preferred are formoterol (fumarate) and salmeterol (xinafoate), and most preferred is salmeterol (xinafoate).
  • the inhaled corticosteroid is preferably budesonide, beclomethasone (dipropionate), ciclesonide, flunisolide, fluticasone (propionate), mometasone (furoate) and triamcinolone (acetonide). More preferred are budesonide, beclomethasone (dipropionate) and fluticasone (propionate), and most preferred is fluticasone (propionate).
  • any preferred salt/ester forms are indicated in parentheses.
  • a triple combination product comprises the long-acting muscarinic antagonist glycopyrronium, the long-acting p 2 -agonist salmeterol and the inhaled corticosteroid fluticasone.
  • the long-acting muscarinic antagonist is glycopyrronium bromide
  • the long-acting p 2 -agonist is salmeterol xinafoate
  • the inhaled corticosteroid is fluticasone propionate.
  • a double combination product comprises the long-acting muscarinic antagonist glycopyrronium and the long-acting p 2 -agonist salmeterol.
  • the long-acting muscarinic antagonist is glycopyrronium bromide and the long-acting p 2 -agonist is salmeterol xinafoate.
  • a double combination product comprises the long-acting muscarinic antagonist glycopyrronium and the inhaled corticosteroid is fluticasone.
  • the long-acting muscarinic antagonist is glycopyrronium bromide and the inhaled corticosteroid is fluticasone propionate.
  • the process to provide a double or triple combination dry powder medicament provides stable and well-performing inhalable formulations, and comprises mixing a combination of a long-acting muscarinic antagonist and long-acting p 2 -agonist and/or inhaled corticosteroid, in particular, mixing a long-acting p 2 -agonist and/or the inhaled corticosteroid and a coarse carrier to form a first blend using a high-energy mixing and a long-acting muscarinic antagonist and coarse carrier using a low-energy mixing process.
  • the long-acting p 2 -agonist and/or the inhaled corticosteroid and coarse carrier are then combined with the long-acting muscarinic antagonist and coarse carrier and mixed to form a final medicament blend.
  • the final medicament blends are prepared using low-energy mixing conditions.
  • the particle sizes (mass median aerodynamic diameter, MMAD) of the long-acting muscarinic antagonist, long-acting p 2 -agonist and inhaled corticosteroid used within the process of the embodiments are each less than 10 ⁇ in size, more preferably 1- 4 ⁇ .
  • MMAD may be measured using a next generation impactor (NGI).
  • NTI next generation impactor
  • This particle size ensures that the particles effectively adhere to the coarse carrier during mixing, and also that the particles disperse and become entrained in the air stream and deposited in the lower lung (i.e. upon actuation of an inhaler device).
  • NTI next generation impactor
  • the volume-based particle size distribution based on the diameter by volume, as measured by laser diffraction, may also be specified.
  • the appropriate particle size of the long-acting ⁇ 2 - agonist and inhaled corticosteroid may be provided by the lyophilisation process described hereinabove although further micronisation may be performed by grinding in a mill, e.g. an air jet, ball or vibrator mill, by sieving, by crystallization, by spray- drying or by further lyophilisation.
  • the appropriate particle size of glycopyrronium bromide is provided by wet polishing.
  • Examples of coarse grade carriers for preparing an inhalable dry powder include polysaccharides, e.g. dextrose, fructose, glucose, lactose, mannitol, maltitol, mannose, sorbitol, sucrose, trehalose, xylitol and combinations thereof, preferably lactose and most preferably alpha-lactose monohydrate is used.
  • the particle size of the carrier should be such that it can be entrained in an air stream but not deposited in the key target sites of the lung. Accordingly, the carrier preferably has a mean particle size of 40 microns or more, more preferably the carrier particles have a VMD of 50-250 microns. The particle size may be determined using laser light scattering (Sympatec GmbH, Claasthal- Zellerfeld, Germany).
  • substantially all particles of the coarse grade lactose carrier are less than 300 ⁇ in size.
  • the lactose is preferably a- lactose monohydrate (e.g. from DMV Fonterra Excipients).
  • the coarse grade carrier may contain inherent fine content (i.e. fine lactose). Such lactose has a particle size less than 10 ⁇ in size, more likely 1-5 ⁇ . Inherent fine content contained within the coarse carrier can be measured by laser diffraction in air, e.g. with a Sympatec HELOS/BF equipped with a RODOS dispenser and VIBRI feeder unit. In the context of the embodiments, such inherent fine content is not to be understood as a ternary excipient.
  • first blend and second blend are mixed together in a weight ratio of 0.5-10:1 to form the final blend pre-mix, prior to mixing of the final blend.
  • first blend and second blend are mixed together in a weight ratio of 2:1 to form the final blend pre-mix, prior to mixing of the final blend.
  • the long-acting muscarinic antagonist is present in an amount of 0.1-0.8 %w/w
  • the long-acting p 2 -agonist is present in an amount of 0.1-0.8 %w/w
  • the inhaled corticosteroid is present in an amount of 1.0-5.0 %w/w.
  • the embodiments also provide a double or triple combination dry powder medicament obtainable by the process as set out herein.
  • the powder medicament is distinguished over powders prepared by other techniques based on the different interaction between the actives and the carrier, as evidenced by the blend uniformity, stability and the maintenance of the aerodynamic particle size distribution over time.
  • the long-acting muscarinic antagonist is also in a more stable form, with low levels of amorphous character, electrostatic charge and hygroscopicity.
  • compositions of the embodiments can be useful for treating respiratory disorders (e.g. asthma and COPD).
  • respiratory disorders e.g. asthma and COPD.
  • the dry powder composition may be metered and filled into capsules, e.g. gelatin or hydroxypropyl methylcellulose capsules, such that the capsule contains a unit dose of active ingredient.
  • capsules e.g. gelatin or hydroxypropyl methylcellulose capsules
  • the total amount of composition will depend on the size of the capsules and the characteristics of the inhalation device with which the capsules are being used. However, typical examples of total fill weights of dry powder per capsule are 1-25 mg.
  • the dry powder composition according to the embodiments may be filled into the reservoir of a multi-dose dry powder inhaler (MDPI), for example of the type disclosed in WO 92/10229.
  • MDPI multi-dose dry powder inhaler
  • Such inhalers comprise a chassis, a dosing chamber, a mouthpiece and the medicament.
  • the dry powder formulation may be presented in an inhaler, e.g. in the reservoir of a multi-dose dry powder inhaler (MDPI), for example the inhalers sold under the brand name Respiclick® or Spiromax® and the inhalers described in WO 92/10229 and WO 201 1/054527.
  • MDPI multi-dose dry powder inhaler
  • Such inhalers comprise a chassis, a dosing chamber, a mouthpiece and the medicament.
  • a 0.3% w/w glycopyrronium bromide (GPB) blend was produced by first tumble mixing lactose with GPB to produce a 0.9% w/w GPB blend.
  • the lactose and GPB were mixed in a tumbler mixer at 46 rpm for 10 minutes.
  • the obtained 0.9 %w/w GPB blend was then mixed with lactose in the weight ratio of 1 :2 (25 g: 50 g).
  • the lactose and 0.9% w/w GPB blend were mixed in a tumbler mixer at 46 rpm for 10 minutes.
  • the resulting product is a 0.3% w/w GPB blend.
  • the GPB blend was subsequently filled into RespiClick® inhalers for chemical and aerosol performance testing and labelled as GPB mono 15 meg.
  • a 0.6% w/w glycopyrronium bromide (GPB) blend was produced by first tumble mixing lactose with GPB to produce a 1.8% w/w GPB blend.
  • the lactose and GPB were mixed in a tumbler mixer at 46 rpm for 10 minutes.
  • the obtained 1.8% w/w GPB blend was then mixed with lactose in the weight ratio of 1 :2 (25 g: 50 g).
  • the lactose and 1.8% w/w GPB blend were mixed in a tumbler mixer at 46 rpm for 10 minutes.
  • the resulting product is a 0.6% w/w GPB blend.
  • the GPB blend was subsequently filled into RespiClick® inhalers for chemical and aerosol performance testing and labelled as GPB mono 30 meg.
  • Fluticasone propionate (Fp) and salmeterol xinafoate (Sx) were blended together with alpha-lactose monohydrate at the concentration of 6.56% w/w Fp and 0.60% w/w Sx using a PharmaConnectTM high shear mixer (process conditions: 1000 rpm chopper speed and 434 rpm impeller speed) for a duration of 15 minutes.
  • Glycopyrronium (glycopyrronium bromide or GPB) was blended together with lactose at the concentration of 0.9 %w/w using a Tumbler mixer (process conditions: 46 rpm) for a duration of 10 minutes.
  • the obtained Fp/Sx blend and GPB blend were then mixed at the weight ratio of 2:1 (50g: 25g) using a tumbler mixer (process conditions: 46 rpm) for a duration of 20 minutes to produce the final triple combination blend containing all three actives (Fp, Sx and GPB) at the concentration of 4.37% w/w, 0.40% w/w and 0.30% w/w respectively.
  • the triple combination blend was subsequently filled into RespiClick® inhalers for chemical and aerosol performance testing and labelled as FSG 232/14/15 meg (containing 232 ⁇ g (Fp) 14 ⁇ g (Sx) and 15 Mg (GPB)).
  • Fluticasone propionate (Fp) and salmeterol xinafoate (Sx) were blended together with alpha-lactose monohydrate at the concentration of 6.56% w/w Fp and 0.60% w/w Sx using a PharmaConnectTM high shear mixer (process conditions: 1000 rpm chopper speed and 434 rpm impeller speed) for a duration of 15 minutes.
  • Glycopyrronium (Glycopyrronium bromide or GPB) was blended together with lactose at a concentration of 1.8% w/w using a Tumbler mixer (process conditions: 46 rpm) for a duration of 10 minutes.
  • the obtained Fp/Sx blend and GPB blend at the weight ratio of 2:1 were then mixed using a tumbler mixer (process conditions: 46 rpm) for a duration of 20 minutes to produce the final triple combination blend containing all three actives (Fp, Sx and GPB) at the concentration of 4.37% w/w, 0.40% w/w and 0.60% w/w respectively.
  • the triple combination blend was subsequently filled into RespiClick® inhalers for chemical and aerosol performance testing and labelled as FSG 232/14/30 meg (containing 232 ⁇ g (Fp) 14 ⁇ g (Sx) and 30 ⁇ g (GPB)).
  • a 1 kg batch of Fp/Sx/lactose (6.56% w/w Fp and 0.60% w/w Sx) was mixed under high-energy high-shear mixing conditions using a PharmaConnectTM high shear mixer (process conditions: 1000 rpm chopper speed and 434 rpm impeller speed) for a duration of 15 minutes.
  • the obtained blend was further mixed with lactose in a tumbler mixer (process conditions: 46 rpm) for a duration of 20 minutes at a ratio of 1 :2 (25 g: 50 g) to obtain an Fp/Sx/lactose blend (4.37% w/w Fp and 0.40%w/w Sx).
  • the formulation was subsequently filled into RespiClick® inhalers for chemical and aerosol performance testing and labelled as FS 232/14 meg (containing 232 ⁇ g (Fp) and 14 ⁇ g (Sx)).
  • Table 2 provides the chemical stability data for the mono (GPB), combination (FSG) and the comparative (FS) formulations.
  • Each of the product blends were prepared according to Examples 1 and 2 and stored in a dry powder within an inhaler. In each case the formulations were wrapped with desiccant in foil and placed in an accelerated testing chamber at 40°C and 75% RH (relative humidity).
  • Table 2.1 provides the percentage impurity data for glycopyrronium bromide extracted from the samples in Table 2.
  • Tables 3, 4 and 5 demonstrate the aerodynamic particle size data (APSD) for glycopyrronium bromide fluticasone propionate, salmeterol xinafoate and respectively for GPB mono and FSG triple products and FS comparative.
  • APSD aerodynamic particle size data

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Selon les modes de réalisation, l'invention concerne un médicament inhalable en poudre sèche contenant du glycopyrronium et un support grossier, le médicament ayant une uniformité de mélange de ± 10 % sans avoir recours à du stéarate de magnésium ou à d'autres agents ternaires. Les modes de réalisation concernent également des produits de combinaison contenant un β2-agoniste d'action prolongée, tel que le glycopyrronium, conjointement avec un β2-agoniste d'action prolongée et/ou un corticostéroïde inhalé. Le mélange à faible énergie est employé pour obtenir l'uniformité du mélange sans dépendre du stéarate de magnésium ou d'autres agents ternaires.
PCT/US2018/052024 2017-09-20 2018-09-20 Médicament inhalable en poudre sèche comprenant du glycopyrronium WO2019060595A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560892P 2017-09-20 2017-09-20
US62/560,892 2017-09-20

Publications (1)

Publication Number Publication Date
WO2019060595A1 true WO2019060595A1 (fr) 2019-03-28

Family

ID=63841024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/052024 WO2019060595A1 (fr) 2017-09-20 2018-09-20 Médicament inhalable en poudre sèche comprenant du glycopyrronium

Country Status (1)

Country Link
WO (1) WO2019060595A1 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010229A1 (fr) 1990-12-15 1992-06-25 Norton Healthcare Limited Dispositif distributeur de medicament en poudre
WO2004019985A1 (fr) 2002-08-29 2004-03-11 Cipla Ltd Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
WO2005082413A2 (fr) * 2004-02-27 2005-09-09 Altana Pharma Ag Combinaison de ciclesonide et de glycopyrronium
WO2005105043A2 (fr) 2004-04-30 2005-11-10 Vectura Limited Compositions pharmaceutiques
WO2007071313A2 (fr) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combinaison d'anticholinergiques, de glucocorticoïdes, de bêta 2-agonistes, d'inhibiteur des pde4 et d'antileucotriène pour le traitement de maladies inflammatoires
WO2008102128A2 (fr) 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
WO2011054527A1 (fr) 2009-11-06 2011-05-12 Norton Healthcare Limited Adaptateur d'écoulement d'air pour inhalateur de poudre sèche actionné par la respiration
WO2011069197A1 (fr) 2009-12-08 2011-06-16 The University Of Sydney Formulations inhalables
WO2014118532A1 (fr) * 2013-01-31 2014-08-07 Prosonix Limited Compositions pharmaceutiques contenant des particules cristallines multi-composant appropriées pour être utilisées dans un traitement par inhalation
WO2014141135A1 (fr) * 2013-03-14 2014-09-18 Novartis Ag Agglomérats inhalables de particules de support poreuses et médicament micronisé
WO2015004243A1 (fr) 2013-07-11 2015-01-15 Chiesi Farmaceutici S.P.A. Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation
WO2016071862A1 (fr) * 2014-11-05 2016-05-12 Glenmark Pharmaceuticals Limited Composition pharmaceutique inhalable comportant du glycopyrronium
US20170136034A1 (en) * 2015-11-16 2017-05-18 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010229A1 (fr) 1990-12-15 1992-06-25 Norton Healthcare Limited Dispositif distributeur de medicament en poudre
WO2004019985A1 (fr) 2002-08-29 2004-03-11 Cipla Ltd Produits et compositions pharmaceutiques comprenant des agents anticholinergiques specifiques, des agonistes beta-2 et des corticosteroides
WO2005082413A2 (fr) * 2004-02-27 2005-09-09 Altana Pharma Ag Combinaison de ciclesonide et de glycopyrronium
WO2005105043A2 (fr) 2004-04-30 2005-11-10 Vectura Limited Compositions pharmaceutiques
WO2007071313A2 (fr) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combinaison d'anticholinergiques, de glucocorticoïdes, de bêta 2-agonistes, d'inhibiteur des pde4 et d'antileucotriène pour le traitement de maladies inflammatoires
WO2008102128A2 (fr) 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
WO2011054527A1 (fr) 2009-11-06 2011-05-12 Norton Healthcare Limited Adaptateur d'écoulement d'air pour inhalateur de poudre sèche actionné par la respiration
WO2011069197A1 (fr) 2009-12-08 2011-06-16 The University Of Sydney Formulations inhalables
WO2014118532A1 (fr) * 2013-01-31 2014-08-07 Prosonix Limited Compositions pharmaceutiques contenant des particules cristallines multi-composant appropriées pour être utilisées dans un traitement par inhalation
WO2014141135A1 (fr) * 2013-03-14 2014-09-18 Novartis Ag Agglomérats inhalables de particules de support poreuses et médicament micronisé
WO2015004243A1 (fr) 2013-07-11 2015-01-15 Chiesi Farmaceutici S.P.A. Formulation de poudre sèche comportant un anticholinergique, un corticostéroïde et un bêta-adrénergique pour l'administration par inhalation
WO2016071862A1 (fr) * 2014-11-05 2016-05-12 Glenmark Pharmaceuticals Limited Composition pharmaceutique inhalable comportant du glycopyrronium
US20170136034A1 (en) * 2015-11-16 2017-05-18 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. E. AULTON: "Aulton's Pharmaceutics: The Design and Manufacture of Medicines", 2007, ELSEVIER LIMITED
X.M ZENG ET AL.: "Particulate Interactions in Dry Powder Formulations for Inhalation", 2000, TAYLOR & FRANCIS

Similar Documents

Publication Publication Date Title
CA2693577C (fr) Medicament sous forme de poudre seche
CA2749231C (fr) Composition pharmaceutique a inhaler
EP3527199B1 (fr) Formulation de poudre sèche comprenant un corticostéroïde et un béta-adrénergique pour l'administration par inhalation
MX2008016356A (es) Composiciones de sal de glicopirronio para inhalacion.
CZ20023437A3 (cs) Práškový farmaceutický prostředek pro inhalátory a způsob jeho výroby
KR20170118975A (ko) 정전하가 감소된 입자를 제공하는 방법
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
WO2019067708A1 (fr) Procédé pour diminuer la taille de particules
JP2017530993A (ja) 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物
WO2019060604A1 (fr) Médicament inhalable
EP1560567A1 (fr) Compositions pour inhalation contenant une proportion elevee de medicament
WO2019060595A1 (fr) Médicament inhalable en poudre sèche comprenant du glycopyrronium
US20180325815A1 (en) Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN107213141A (zh) 用于吸入的药物组合物
CN114514020A (zh) 用于吸入用干粉制剂的新型载体颗粒
WO2024119058A2 (fr) Formulation d'un inhibiteur pan-jak
TR2023002209T2 (tr) Kuru toz i̇nhalasyon kompozi̇syonlarinin hazirlanmasi i̇çi̇n bi̇r yöntem
WO2024010539A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation à l'aide de différents mélangeurs
WO2024010538A1 (fr) Procédé de préparation de compositions de poudre sèche pour inhalation à l'aide de différents mélangeurs
WO2022045994A1 (fr) Procédé de préparation de compositions en poudre sèche pour inhalation
TR2023002207T2 (tr) İnhalasyon i̇çi̇n kuru toz kompozi̇syonlarinin üreti̇m yöntemi̇
EP3621590A1 (fr) Procédé de préparation d'une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18786119

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18786119

Country of ref document: EP

Kind code of ref document: A1